Abcam, ab265295, Human VAC14 knockout HeLa cell line

Size: 2 x 1000000Cells / vial / 1000000Cells / vial
VAC14 KO cell line available to order. KO validated by. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 1 and 1 bp insertion in exon 1. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Form:LiquidSee storage information,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 1 and 1 bp insertion in exon 1,
Disease:Adenocarcinoma

Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-VAC14, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
VAC14 also known as ArPIKfyve is a regulatory protein with a molecular weight of roughly 100 kDa. It is expressed in various tissues but particularly notable in the brain. Mechanically VAC14 works with FIG4 and PIKFYVE in a complex that regulates the levels of phosphatidylinositol 35-bisphosphate (PI(35)P2) in cells. It interacts directly with PIKFYVE to control its kinase activity which is important for maintaining the balance of phosphoinositides.
Biological function summary
VAC14 takes an important role in phosphoinositide metabolism and is part of the PIKfyve complex which consists of PIKFYVE and FIG4. This complex regulates the synthesis of PI(35)P2 a lipid second messenger involved in various cellular processes. Through this regulation VAC14 influences membrane trafficking endosome-to-lysosome transport and lysosomal homeostasis. Proper functioning of VAC14 is essential for cellular integrity and response to environmental changes especially in neuronal cells.
Pathways
VAC14 involves itself in the phosphoinositide signaling pathway and the lysosomal pathway. This protein forms a module with PIKFYVE and FIG4 to control the production of PI(35)P2 which is important for endolysosomal dynamics. VAC14's activity influences autophagic flux and endosomal maturation processes integral to cellular homeostasis. The modulation of these pathways ensures proper intracellular processing and material degradation which is linked to cellular health and stress responses.
VAC14 has associations with Charcot-Marie-Tooth disease (CMT) and fibrotic lung disease. Mutations affecting VAC14 can lead to the malformation of neuronal axons and defects in both motor and sensory neurons in CMT. In these diseases VAC14 interacts with FIG4 where mutations in either protein can disrupt PI(35)P2 levels leading to neuropathy. Understanding the role of VAC14 in these contexts opens avenues for targeted therapeutic interventions in related neurological and fibrotic disorders.